Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,319Revenue $M241Net Margin (%)4.2Altman Z-Score8.1
Enterprise Value $M2,278EPS $0.3Operating Margin %7.5Piotroski F-Score7
P/E(ttm)233Beneish M-Score-2.5Pre-tax Margin (%)4.4Higher ROA y-yY
Price/Book11.110-y EBITDA Growth Rate %--Quick Ratio1.2Cash flow > EarningsY
Price/Sales10.55-y EBITDA Growth Rate %--Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)3.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)5.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M36.8ROIC % (ttm)11.8Gross Margin Increase y-yY

Gurus Latest Trades with PCRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCRXKen Fisher 2015-12-31 Add$36.62 - $79.39
($56.9)
$ 63.1011%Add 4.15%6,197
PCRXMariko Gordon 2015-09-30 Add0.94%$40.95 - $70
($61.25)
$ 63.103%Add 56.02%1,042,012
PCRXGeorge Soros 2015-09-30 Sold Out -0.39%$40.95 - $70
($61.25)
$ 63.103%Sold Out0
PCRXRon Baron 2015-09-30 Buy $40.95 - $70
($61.25)
$ 63.103%New holding6,900
PCRXKen Fisher 2015-09-30 Add$40.95 - $70
($61.25)
$ 63.103%Add 23.96%5,950
PCRXGeorge Soros 2015-06-30 Buy 0.39%$65.78 - $92.39
($78.91)
$ 63.10-20%New holding531,800
PCRXRon Baron 2015-06-30 Sold Out -0.03%$65.78 - $92.39
($78.91)
$ 63.10-20%Sold Out0
PCRXMariko Gordon 2015-06-30 Add0.02%$65.78 - $92.39
($78.91)
$ 63.10-20%Add 1.19%667,877
PCRXJoel Greenblatt 2015-06-30 Sold Out -0.01%$65.78 - $92.39
($78.91)
$ 63.10-20%Sold Out0
PCRXMariko Gordon 2015-03-31 Reduce-0.12%$85.01 - $119.27
($101.46)
$ 63.10-38%Reduce -4.30%659,998
PCRXGeorge Soros 2015-03-31 Sold Out -0.084%$85.01 - $119.27
($101.46)
$ 63.10-38%Sold Out0
PCRXRon Baron 2015-03-31 Add0.01%$85.01 - $119.27
($101.46)
$ 63.10-38%Add 22.79%82,380
PCRXJoel Greenblatt 2015-03-31 Buy 0.01%$85.01 - $119.27
($101.46)
$ 63.10-38%New holding9,319
PCRXMariko Gordon 2014-12-31 Reduce-0.54%$86.02 - $107.8
($94.65)
$ 63.10-33%Reduce -15.33%689,628
PCRXGeorge Soros 2014-12-31 Buy 0.08%$86.02 - $107.8
($94.65)
$ 63.10-33%New holding87,000
PCRXJoel Greenblatt 2014-12-31 Sold Out -0.01%$86.02 - $107.8
($94.65)
$ 63.10-33%Sold Out0
PCRXKen Fisher 2014-12-31 Buy $86.02 - $107.8
($94.72)
$ 63.10-33%New holding4,800
PCRXMariko Gordon 2014-09-30 Reduce-1.21%$83.31 - $108.26
($97.65)
$ 63.10-35%Reduce -28.09%814,470
PCRXRon Baron 2014-09-30 Reduce-0.03%$83.31 - $108.26
($97.65)
$ 63.10-35%Reduce -59.75%62,139
PCRXJoel Greenblatt 2014-09-30 Reduce$83.31 - $108.26
($97.65)
$ 63.10-35%Reduce -26.78%6,946
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Braunstein ScottSVP, Strategy & Corp. Dev. 2016-01-29Buy2,000$58.927.09view
Jones James BSVP & Chief Medical Officer 2016-01-27Buy500$62.50.96view
STACK DAVID MCEO and Chairman 2016-01-15Sell15,000$63.84-1.16view
LONGENECKER JOHN P PHDDirector 2016-01-12Buy300$66.55-5.18view
Jones James BSVP & Chief Medical Officer 2016-01-12Buy1,000$66-4.39view
HASTINGS PAUL JDirector 2015-11-20Sell3,000$605.17view
STACK DAVID MPresident, CEO and Chairman 2015-10-15Sell15,000$37.5767.95view
Scibetta James SSVP, CFO 2015-09-11Buy5,000$61.372.82view
HASTINGS PAUL JDirector 2015-08-17Sell3,000$60.025.13view
STACK DAVID MPresident, CEO and Chairman 2015-07-15Sell15,000$67.78-6.9view

Press Releases about PCRX :

Quarterly/Annual Reports about PCRX:

    News about PCRX:

    Articles On GuruFocus.com
    Mariko Gordon Nearly Doubles Stake in Forward Air Jan 04 2016 
    Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
    Mariko Gordon's First Quarter Top Five May 15 2014 
    Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
    Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 27 2011 
    Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 16 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CEO David M Stack buys 5,000 Shares Feb 11 2011 

    More From Other Websites
    Shire's NDA Resubmission for Lifitegrast Accepted by FDA Feb 05 2016
    Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) to Ring The Nasdaq Stock Market Opening Bell Feb 02 2016
    Pacira Pharma upgraded by BofA/Merrill Jan 29 2016
    Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 22,... Jan 22 2016
    Pacira Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PCRX) : January 12, 2016 Jan 12 2016
    Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 12,... Jan 12 2016
    PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 08 2016
    PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 07 2016
    Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million Jan 07 2016
    Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million Jan 07 2016
    Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference Dec 28 2015
    Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference Dec 28 2015
    Pacira Rose on the FDA’s Favorable Decision on EXPAREL Dec 21 2015
    PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Dec 18 2015
    Pacira Resolves Litigation Related to Exparel with the FDA Dec 15 2015
    What's next for Valeant? Dec 15 2015
    Pacira Pharma Soars on Settled FDA Case Dec 15 2015
    Pacira Pharmaceuticals (PCRX) Stock Surges After Regulators Resolve Free Speech Dispute Dec 15 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK